News

Oslo, Norway, 20 May 2026: Reference is made to the Annual General Meeting (the “AGM”) of Oncoinvent ASA (the “Company”) earlier today where the nomination committee’s proposal for remuneration for the members of the Board was approved. The AGM approved the following share option remuneration to the Board. Chair of the Board: 1,708 share options

20 May 2026, Oslo Norway: The Annual general meeting of the Company was held today, 20 May 2026, by electronic means through Lumi AGM. All proposals on the agenda were adopted in accordance with the proposals set out in the notice dated 28 April 2026. The complete minutes of the ordinary general meeting are attached

Oslo, Norway, 5 May 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the “Company“) on 8 January 2026 regarding the resolution by the extraordinary general meeting to decrease the share capital of the Company by NOK 222,800,997, from NOK 223,920,600 to NOK 1,119,603, through a reduction of the nominal value

Oslo, Norway, 28 April 2026 – Oncoinvent ASA (ONCIN), will be holding its Annual General Meeting virtual on 20 May 2026 at 10:00 hours (CEST). The notice and agenda of the annual general meeting is attached hereto, including further information on advance voting, power of attorney and physical participation. The notice will be sent to

Oslo, Norway, 11 March 2026: The Board of Directors has today resolved to grant CEO Øystein Soug 31,884 share options in the Company under the Company’s long term incentive program, each with a strike price of NOK 42.98, equal to the volume weighted average share price the last day before the grant. See the attached

9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose Oslo, Norway, 17 February 2026 – Oncoinvent (OSE: ONCIN), a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it

Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is pleased to invite investors, analysts, and stakeholders to a live webcast event at 9:30 AM CET on Thursday, 26 February 2026.   During

First patient enrolled in newly activated site   Oslo, Norway, 29 January 2026: Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announces that the first patient has been enrolled at one of the newly activated sites in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarian

Oslo, Norway, 20 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the “Company“) on 8 January 2026 regarding the Company’s extraordinary general meeting resolving a reverse share split of the Company’s shares in the ratio 100:1. The reverse share split has today been registered with the Norwegian Register of

Issuer name: Oncoinvent ASA Ex. date: 19 January 2026Type of corporate action: Reverse share split Other information:– Reverse split ratio: 100:1, i.e. one hundred (100) old shares give one (1) new share– New par value per share: NOK 50– New ISIN for the company’s shares: ISIN NO 0013711713– New number of shares outstanding: 4,478,412 shares

Oslo, Norway, 15 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the “Company“) on 8 January 2026 regarding the resolution by the extraordinary general meeting of the Company to increase the share capital in connection with the issuance of 75 new shares to Abakus Invest AS for purposes of

Oslo, Norway, 14 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the “Company“) on 8 January 2026 regarding the resolution by the Company’s extraordinary general meeting to carry out a reverse share split of the Company’s shares. Key information related to the reverse share split, including the relevant key

Oslo, Norway, 13 January 2026: Reference is made to the announcement made by Oncoinvent ASA (“Oncoinvent” or the “Company”) 31 October 2025 regarding the appointment of Ramzi Amri as the new CEO of the Company as of January 2026. The Board of Directors has resolved to grant Ramzi Amri 5,430,000 share options in the Company

Oslo, Norway, 8 January 2026: An extraordinary general meeting of the Company was held today, 8 January 2026, by electronic means through Lumi AGM. The general meeting, inter alia, resolved i) audited interim balance sheet, ii) a reverse share split, iii) a capital reduction, and iv) proxy to the Board of Directors. The complete minutes

Oslo, Norway, 22 December 2025: Oncoinvent ASA (“Oncoinvent” or the “Company”) (OSE: ONCOIN), a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announce that the Board of Directors has granted options to employees. As previously communicated and with the objective of aligning share option participants’ interests with those of the shareholders of

10 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).

Oslo, Norway, 8 December 2025 – Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The results from the first patients have been published in the respected peer-reviewed journal Gynecologic

8 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”). Further,

5 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).

5 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”).

2 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company“) on 14 November 2025 and on 17 November 2025, regarding the commencement of the subscription period in the fully underwritten rights issue of 260,000,000 new shares in the Company (the “Rights Issue“) and the receipt of subscription rights

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

27 November 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company“) on 14 November 2025 and on 17 November 2025, regarding the commencement of the subscription period in the fully underwritten rights issue of 260,000,000 new shares in the Company (the “Rights Issue“) and the receipt of subscription rights

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

14 November 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue in the Company raising gross proceeds of NOK 130 million (the “Rights Issue”). In connection with the Rights Issue, tradable

14 November 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue in the Company raising gross proceeds of NOK 130 million (the “Rights Issue”). In connection with the Rights Issue, tradable

Issuer name: Oncoinvent ASA Ex. date: 12 November 2024 Type of corporate action: Rights issue This information is published in accordance with the requirements of the Continuing Obligations.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

Oncoinvent invites for Q3 2025 company update in English on Tuesday 4th of November at 08:30 AM CEST. The presentation will be broadcasted live on https://channel.royalcast.com/landingpage/hegnarmedia/20251104_9/. There will be a possibility for Q&A. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting

Oslo, 3 November 2025: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company“) on 29 October 2025 regarding the completion of the merger between the Company and the former Oncoinvent ASA (reg. no. 995 764 458) (“Oncoinvent“) (the “Merger“). In connection with completion of the Merger, the former shareholders of

Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January.  Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. The company would like to thank Mr Kvam for his valuable work and dedication over the past years.

Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ASA and Oncoinvent ASA (“Oncoinvent“) through a statutory triangular merger (the “Merger“), including the announcements made on 4 August 2025 regarding approval of the Merger by the extraordinary general meetings of the two

Bergen, 29 October 2025; Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGenBio ASA and Oncoinvent ASA (“Oncoinvent“) regarding key dates for completion of the combination of the two companies through a statutory triangular merger (the “Merger“). Reference is further made to the stock exchange announcement made on

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by BerGenBio ASA (OSE: BGBIO) (“BerGenBio“) and Oncoinvent ASA (OSE: ONCIN) (“Oncoinvent“) regarding the combination of the two companies through a statutory triangular merger (the “Merger“), and the announcements on 4 August 2025

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF

Bergen, 4 August 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by BerGenBio ASA (the “Company”) and Oncoinvent ASA (“Oncoinvent”) regarding the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS though a statutory triangular merger (the “Merger”). An extraordinary general meeting of the Company was held

Bergen, Norway – 3 July 2025: BerGenBio ASA (OSE:BGBIO) will hold an Extraordinary General Meeting virtually on 4 August 2025 at 12:00 PM (CEST).   The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF

Bergen, 26 June 2025: BerGenBio ASA held its annual general meeting today digitally through Lumi AGM. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2024 annual accounts, election of a member to and the remuneration the board

Bergen, 3 June 2025 – Reference is made to previous stock exchange announcements from BerGenBio ASA (“BerGenBio” or the “Company”) dated 25 February 2025 and 17 March 2025 regarding the Company’s ongoing strategic review process. Strategic review process is ongoing With reference to the announcement 17 March 2025, engaging DNB Carnegie as financial advisor for

Bergen, Norway – 3 June 2025: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 26 June 2025 at 10:00 hours (CEST).   The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other

The article identifies promising survival results in relapsed/refractory AML patients warranting further study   Bergen, Norway – 26 March 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the publication of a peer-reviewed article entitled “Bemcentinib as Monotherapy and in Combination with Low-Dose

Bergen, Norway, March 17, 2025 – Reference is made to the stock exchange announcement on 25 February 2025 from BerGenBio ASA (OSE: BGBIO) (the “Company”), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for serious diseases, in which the Company amongst other things announced that it will explore strategic alternatives. The

Bergen, Norway, February 26, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended December 31, 2024, and provided a business update.   Highlights, including post period:   BGBC016 1L NSCLC STK11m Study Yesterday the company

Bergen, Norway, February 25, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for serious diseases today announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with

Bergen, Norway, 18 February 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the fourth quarter 2024 on Wednesday 26 February 2025. BerGenBio’s senior management team will provide a business update at 10:30 am CET. The presentation will webcast

Bergen, Norway, January 7, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio

BERGEN, Norway, November 26, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that the Company will present at the DNB Nordic Healthcare Conference today in Oslo, Norway at 14:45-15:05 CET.   Chief Executive Officer Olav Hellebø will provide a business update including

Bergen, Norway, November 20, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the position on November 21, 2024.   Mr. Hellebø brings three decades of experience in the pharmaceutical

Bergen, Norway, November 13, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended September 30, 2024, and provided a business update. Highlights, including post period: BGBC016 1L NSCLC STK11m Study Ph1b enrollment

Bergen, Norway, 10 October 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical need, announces today that CEO, Martin Olin will be leaving the company to pursue other opportunities. Martin will remain in his position during a transition period. “On behalf of the Board of

Bergen, Norway,10 October 2024 – An Extraordinary general meeting of BerGenBio ASA was virtually held today 10 October 2024 at 10.00 CEST.   All proposals were resolved as presented in the notice convening the extraordinary general meeting distributed on 19 September 2024 as further set out in the minutes from the extraordinary general meeting attached

Ph1b data support safety, predictable PK and adequate plasma exposure Bergen, Norway, October 7, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung

Bergen, Norway, September 9, 2024- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announcedtoday that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference held in New York City, September 9-11, 2024.  Chief Executive Officer Martin Olin will provide a business

Bergen, Norway, August 20, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today a collaboration with Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, to advance the clinical development of BerGenBio’s selective AXL

Bergen, 15 August 2024: Reference is made to the stock exchange announcement made by BerGenBio ASA (the “Company”) on 23 May 2024 regarding the Company’s general meeting resolving a share capital decrease by reducing the nominal value of the Company’s shares by NOK 9 from NOK 10 to NOK 1, resulting in a decrease of

Bergen, Norway, 13 August 2024- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2024 on Wednesday 21 August 2024. The briefing will take place at the Conference “Vestland på Børs” at 09:45 am CEST

BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to initiate second dose in Ph2a of BGBC016 trial Bergen, Norway, July 29, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and Safety Monitoring Board

Bergen, Norway, 26 June 2024 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees. The annual general meeting in the Company on 23 May 2024 approved the share option program and

Bergen, Norway, 3 June 2024. Reference is made to the stock exchange announcement made by BerGenBio ASA (the “Company”) on 23 May 2024 regarding the Company’s annual general meeting resolving a reverse share split of the Company’s shares in the ratio 100:1. The reverse share split has today been registered with the Norwegian Register of

Issuer name: BerGenBio ASAEx. date: 30 May 2024Type of corporate action: Reverse share splitReverse split ratio: One hundred (100) old shares give one (1) new share. New par value per share: NOK 10 New ISIN: NO 001 3251173 New number of shares outstanding: 39,087,116 For further information, please contact: Martin Olin, CEO, BerGenBio ASAir@bergenbio.com Rune

Bergen, Norway, May 29, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update. Highlights, including post period: Data Safety Monitoring Board review supported dose escalation in Ph

  Bergen, Norway, May 28, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health

Bergen, Norway, 28 May 2024: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 23 May 2023, regarding the Company’s annual general meeting resolving a reverse share split of the Company’s shares. Key information related to the reverse share split is set out below: Reverse split ratio: 100:1, i.e.

Bergen, Norway, 28 May 2024: Reference is made to the stock exchange announcement by BerGenBio ASA (the “Company”) on 23 May 2024 regarding the Company’s annual general meeting resolving to increase the Company’s share capital by NOK 3.30 by issuance of 33 new shares, each with a nominal value of NOK 0.10 to ensure that

Bergen, 23 May 2024: BerGenBio ASA held its annual general meeting today digitally through Lumi AGM. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2023 annual accounts, election of a member to the board of directors, the

Bergen, Norway, 22 May 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the first quarter 2024 on Wednesday 29 May 2024. BerGenBio’s senior management team will provide a business update at 10:00 am CET. The presentation will webcast live.

Bergen, Norway – 30 April 2024: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 23 May 2024 at 16:00 hours (CEST). The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments

Bergen, Norway, 25 April 2024 – Reference is made to the stock exchange announcement by BerGenBio ASA (the “Company”) on 16 April 2024 regarding the final results of the last exercise period for the warrants (“Warrants”) issued in connection with the rights issue, which resulted in an allocation of 1,106,565,434 new shares in the Company

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS

Bergen, Norway, 15 April 2024 – Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 15 June 2023 regarding the allocation of offer shares and warrants (the “Warrants”) to certain primary insiders and close associates of primary insiders of the Company in connection with the June 2023 rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS

Sarsia Seed AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 4th and 5th April 2024 sold in total 2,940,000 shares in BerGenBio ASA at an average price of NOK 0.1705. Following these transactions, Sarsia Seed AS holds 5,160,000 shares in the Company and 4,050,000

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

Bergen, Norway, 27 March 2024 – Reference is made to the stock exchange announcement from BerGenBio ASA (the “Company”) dated 14 June 2023 regarding the final results of the rights issue of 2,500,000,000 new shares in the Company (the “Offer Shares”), raising gross proceeds of NOK 250 million (the “Rights Issue”), and the allocation and

BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to proceed without study modification Bergen, Norway, March 20, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study

BERGEN, Norway, March 4, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will present at Carnegie’s 27th Annual Nordic Healthcare Seminar to be held on March 5th – 6th, 2024 in Stockholm, Sweden. The presentation will be

Bergen 19 February 2024 – Reference is made to the stock exchange announcement on 7 December 2023 regarding the approval and publication of a prospectus prepared by BerGenBio ASA (the “Company”) for the listing of new shares to be issued by the Company (the “Prospectus”). The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today

Bergen (Norway), February 14, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended December 31, 2023, and provided a business update.  Highlights, including post period Phase 1b part of BGBC016 (1L NSCLC STK11m) progressed as

Bergen, Norway, February 7, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented “Investigating the effects of AXL inhibition during respiratory viral infections” during the 6th Forum on Respiratory Infections

Bergen, Norway, 6 February 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the fourth quarter 2023 on Wednesday 14 February 2024. BerGenBio’s senior management team will provide a business update at 10:00 am CET. The presentation will webcast

BERGEN, Norway, December 15, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Trial Steering Committee of the EU-SolidAct has recommended to discontinue the bemcentinib study arm in the Ph2b EU-SolidAct platform study in hospitalized COVID-19 patients due to

Bergen, Norway, December 12, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the 14th Annual DNB Nordic Healthcare Conference in Oslo, Norway, on Thursday, December 14, 2023, at 12:35pm

Bemcentinib is an oral highly selective AXL inhibitor in development for cancer and severe respiratory infections Final Phase 2 data indicates a favorable safety profile with promising efficacy in AML and MDS patients BERGEN, Norway, December 11, 2023, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe

Bergen, Norway, 8 December 2023 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees.   The annual general meeting in the Company on 22 May 2023 approved the share option program

Bergen 8 December 2023 – Reference is made to the stock exchange announcement by BerGenBio ASA (the “Company”) on 30 November 2023 regarding the final results of the first exercise period for the warrants (“Warrants”) issued in connection with the rights issue, which resulted in an allocation of 68,156,682 new shares in the Company (“New

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THEDISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE

Bergen 21 November 2023 – Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 15 June 2023 regarding the allocation of offer shares and warrants (the “Warrants”) to certain primary insiders and close associates of primary insiders of the Company in connection with the June 2023 rights issue completed

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

BERGEN, Norway, November 14, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended September 30, 2023, and provided a business update. “We are pleased to report continued advancement of our focused strategy to study our

Bergen, Norway, 6 November 2023 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the third quarter 2023 on Tuesday 14 November 2023. BerGenBio’s senior management team will provide a business update at 10:00 am CET. The presentation will webcast live.

Presented at 2023 SITC Meeting – A pre-planned biomarker analysis of patients treated with bemcentinib in combination with KEYTRUDA® (pembrolizumab) yields new understandings- BERGEN, Norway, November 6, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that a poster presentation detailing additional

BERGEN, Norway, November 2, 2023, BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting final results from a clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) will

BERGEN, Norway, October 31, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib, a highly selective AXL inhibitor in combination with

BERGEN, Norway, October 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer (NSCLC) were presented during the European Society

BERGEN, Norway, October 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO)

– Presentation available September 11, 2023 on BGBIO website – BERGEN, Norway, September 11, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for Non-Small Cell Lung Cancer (NSCLC), announcedtoday that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference held in New York

BERGEN, Norway, August 22, 2023- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announcedtoday that additional clinical data of bemcentinib in combination with chemotherapy and with immunotherapy in Non-Small Cell Lung Cancer (NSCLC) have been recently published and accepted for presentation at two upcoming

Bergen, Norway, 16 August 2023- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2023 on Wednesday 23 August 2023. The briefing will take place at the Conference “Vestland på Børs” at 10:45 am CEST

Bergen 29 June 2023: Reference is made to previous stock exchange announcements from BerGenBio ASA (“BerGenBio” or the “Company”) regarding the partially underwritten rights issue of up to 2,500,000,000 new shares (the “Offer Shares”) in the Company, raising gross proceeds of up to NOK 250 million (the “Rights Issue”). Reference is further made to the

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Bergen 27 June 2023: Reference is made to previous stock

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

Bergen 22 June 2023: Reference is made to the stock exchange announcement by BerGenBio ASA (the “Company”) on 14 June 2023 regarding the final results of the partially underwritten rights issue of 2,500,000,000 new shares in the Company (the “Offer Shares”) at a subscription price of NOK 0.10 per new share, raising gross proceeds of NOK

Bergen 22 June 2023: Reference is made to the stock exchange announcement by BerGenBio ASA (the “Company”) on 14 June 2023 regarding the final results of the partially underwritten rights issue of 2,500,000,000 new shares in the Company (the “Offer Shares”) at a subscription price of NOK 0.10 per new share, raising gross proceeds of NOK

Bergen, Norway, June 22, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. “We recently reported the positive readout of several clinical trials that strongly validate

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES

Bergen 15 June 2023: Reference is made to previous stock exchange announcements published by BerGenBio ASA (the “Company”), regarding the partially underwritten rights issue of between 1,687,500,000 and 2,500,000,000 new shares in the Company (the “Offer Shares”) at a subscription price of NOK 0.10 per Offer Share (the “Rights Issue”). In addition, the subscribers in

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE

Bergen 13 June 2023: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 30 May 2023, regarding the commencement of the subscription period in the rights issue (the “Rights Issue”) and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE

Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 30 May 2023, regarding the commencement of the subscription period in the rights issue (the “Rights Issue”) and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the

Bergen 7 June 2023: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 30 May 2023, regarding the commencement of the subscription period in the rights issue (the “Rights Issue”) and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

– Investigator-led Phase IIa study met its primary endpoint of disease control rate at 12 weeks – BERGEN, Norway, June 5, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that an oral presentation detailing the initial results from a Phase IIa

– Artic Securities and Carnegie will host the event on Friday, June 2, 2023, at 11:00 a.m. CEST – BERGEN, Norway, May 30, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will participate in an investor webcast

Bergen 30 May 2023: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) earlier today, 30 May 2023, regarding the commencement of the subscription period in the rights issue (the “Rights Issue”). As part of this process, subscription rights have been allocated to primary insiders and their close associates. Martin

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS

– Oral presentation to reveal data from trial evaluating bemcentinib in relapsed mesothelioma – – Trial-in-Progress poster to be presented regarding the BGBC016 1L STK11m NSCLC trial – BERGEN, Norway, May 25, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced

Sarsia Seed AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 24 May 2023 sold 2,117,900 shares in BerGenBio ASA at an average price of NOK 0.2975. Following this transaction, Sarsia Seed AS holds 0 shares in the Company. Sarsia Development AS, a company closely

Issuer name: BerGenBio ASA Ex. date: 23 May 2023 Type of corporate action: Preferential rights issue This information is published in accordance with the requirements of the Continuing Obligations.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Bergen 22 May 2023. Reference is made to the stock

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. Reference is made to the stock exchange announcement

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

– Management to provide clinical and financial updates, and outline proposed rights issue – – Webcast will take place on Monday, May 15, 2023, at 10 a.m. CEST – BERGEN, Norway, May 9, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END

– In addition to STK11 mutations, KEAP1m identified as being associated with STK11 loss of function – – STK11 loss of function correlated to AXL activation and poorer outcomes in NSCLC – BERGEN, Norway, April 18, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet

– Data on AXL as a therapeutic target in lung cancers to be highlighted at AACR – – Ph1a/2b 1L STK11m NSCLC trial design to be outlined at ELCC – BERGEN, Norway, March 28,2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today

BERGEN, Norway, March 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the Carnegie Nordic Healthcare Conference in Stockholm, Sweden, today March 16, 2023, at 1:45 pm CET. The

– Global trial designed to study the safety, tolerability and efficacy of bemcentinib in combination with current standard of care – BERGEN, Norway, March 9, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the first patient was dosed in a

BERGEN, Norway, February 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the fourth quarter ended December 31, 2022, and provided a business update. A briefing by BerGenBio’s senior management team will take place at 10:00 am

– The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February 16, 2023, at 10:00 AM CET – BERGEN, Norway, February 15, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced topline data from BGBC008,

– Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC – BERGEN, Norway, February 2, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the formation of a scientific advisory board consisting of four world-renowned non-small cell lung cancer

Bergen, Norway, 1 February 2023- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the fourth quarter 2022 on Thursday 16 February 2023. The briefing will take place at 10:00 am CET at: Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor,

BERGEN, Norway, December 8, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the 13th Annual DNB Nordic Healthcare Conference in Oslo, Norway, on Thursday, December 15, 2022, at 11:45am

Bergen, Norway, 21 November 2022 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees. The annual general meeting in the Company 28 April 2022 approved the share option program and authorised

– Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients – – Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations – – Strengthened financial position with support from largest shareholder – BERGEN, Norway, November 15, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,

Bergen, Norway, 8 November 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the third quarter 2022 on Tuesday 15 November 2022. The briefing will take place at 10:00 am CET at: Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor,

BERGEN, Norway, October 25, 2022: BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder in BerGenBio, today announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK

 – Study will assess bemcentinib in combination with current standard of care for 1st line NSCLC – – Approximately 20% of NSCLC patients have STK11 mutations – – First patient is expected to be dosed in 4Q22 – BERGEN, Norway, October 11, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective

BERGEN, Norway, September 27, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Oslo University Hospital announced today that the first patient has been included in a study of BerGenBio’s oral, highly selective AXL inhibitor, bemcentinib, as part of the EU-SolidAct trial

BERGEN, Norway, September 7, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at Pareto Securities’ 13th Annual Healthcare Conference in Stockholm, Sweden, on Wednesday, September 7, 2022, at 8:15am CEST. 

Bergen, Norway, 9 August 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2022 on Tuesday 23 August 2022. The briefing will take place at 10:00 am CET at: Carnegie AS, Fjordalleen 16, Aker

Bergen, Norway,16 June 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Anders Tullgren, Chairman of the Board and primary insider of BerGenBio ASA, has bought 25,000 shares in BerGenBio ASA at an average price of NOK 10.73 per share. The shares are purchased under the sign on bonus agreement approved by the Extraordinary General

Bergen, Norway, 6 June 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce presentation of a poster at the ASCO Annual Meeting to be held from 3rd – 8th June 2022. The poster presentation provides clinical data from a Phase 1 dose

Bergen, Norway, 24 May 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the first quarter 2022. A briefing by BerGenBio’s senior management team will take place at 10:00am CEST today via a webcast presentation, followed by a Q&A

Bergen, Norway, 18 May 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the first quarter 2022 on Tuesday 24 May 2022. A presentation and live webcast by BerGenBio’s senior management team will take place at 10:00 am CET, followed

Bergen, Norway, 16 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the ABG Sundal Collier Life Science Summit taking place on Wednesday 18 May at 11:30 CEST. The presentation slides will

BerGenBio to focus on two key opportunities for its lead compound bemcentinib Strategic focus anchored in strong scientific rationale, supported by dataset from over 600 patients demonstrating bemcentinib’s biological and clinical activity matched with significant unmet medical needs Bergen, Norway,4 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors

Bergen, Norway, 28 April 2022 – Annual general meeting of BerGenBio ASA was virtually held today 28 April 2022 at 10.00 CET. All proposals were resolved as presented in the notice convening the annual general meeting distributed on 7 April 2022, as further set out in the minutes from the annual general meeting attached hereto

Bergen, Norway, 26 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the ArcticSecuritiesBiotech Webinar taking place today at 12:55 CET. The presentation will be made available on the Company’s

Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy BerGenBio to confirm the ACCORD2 data by progressing bemcentinib into EU-SolidAct, a pan-European platform COVID-19 study enrolling up to 500

Bergen, Norway, 25 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that it is presenting data today from its Phase IIa bemcentinib COVID-19 clinical trial (BCBC020) in a poster presentation at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),

Bergen, Norway, 11 April 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the appointment of Cristina Oliva, MD as Chief Medical Officer (CMO), effective 25 April 2022. Cristina joins the senior leadership team heading up clinical development of BerGenBio’s selective AXL inhibitor programs.

Bergen, Norway – 7 April 2022: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 28 April 2022 at 10:00 hours (CEST). The notice, power of attorney and proposal from Nomination Committee are attached to this release. The notice will be sent to all registered shareholders and is available on the Company’s website:

The article identifies the key role of AXL inhibition in restoring response to immune checkpoint blockade therapy in lung cancer with mutations in the STK11/LKB1 gene Bergen, Norway – 17 March 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the publication of

Bergen, Norway, 17 March 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the Carnegie Virtual Nordic Healthcare Seminar taking place today at 15:15 CET. The presentation will be made available

The article identifies the key role of AXL inhibition in restoring response to immune checkpoint blockade therapy in lung cancer with mutations in the STK11/LKB1 gene Bergen, Norway – 17 March 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the publication of

Bergen, Norway, 22 February 2022 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 16 February 2022 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to

Bergen, Norway, 16 February 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the fourth quarter and full year 2021. A briefing by BerGenBio’s senior management team will take place at 10:00am CET today via a webcast presentation, followed

Bergen, Norway,8 February 2022 -BerGenBioASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need,will be announcing its results for thefourthquarter 2021 onWednesday 16 February 2022. A briefing by BerGenBio’s senior management team will take place at 10:00 am CET via a webcast presentation, followed by a Q&A session. The

Bergen, Norway, 27 January 2022 The Board of Directors in BerGenBio ASA (the”Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 10,000 by issuance of 100,000

Bergen/Oslo, Norway 27 January 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs and Oslo University Hospital announced today the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalised COVID-19 patients. The EU-SolidAct trial – European DisCoVeRy for Solidarity: An Adaptive

Bergen, Norway,10 January 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 9,100 shares in BerGenBio ASA at an average price of NOK 20.51 per share. After the transaction Mr. Olin holds 37,100 shares in BerGenBio ASA. Please see the attached document for further

Bergen, Norway,7 January 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 10,000 shares in BerGenBio ASA at an average price of NOK 20.43 per share. After the transaction Mr. Olin holds 28,000 shares in BerGenBio ASA. Please see the attached document for further

Bergen, Norway,7 January 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 10,000 shares in BerGenBio ASA at an average price of NOK 20.03 per share. After the transaction Mr. Olin holds 18,000 shares in BerGenBio ASA. Please see the attached document for further details

Bergen, Norway, 6 January 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces today the appointment of Anders Tullgren to succeed Sveinung Hole as Chairman of the Board of Directors, effective today. Sveinung Hole has been Chairman of the Board since March 2019 and

Bergen, Norway, 6 January 2022 – BerGenBio ASA (OSE:BGBIO) announces that an extraordinary general meeting in the Company was held on 6 January 2022. All proposals were resolved as presented in the notice convening the extraordinary general meeting distributed on 16 December 2022, as further set out in the minutes from the extraordinary general meeting

Bergen, Norway,6 January 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 8,000 shares in BerGenBio ASA at an average price of NOK 19.87 per share. After the transaction Mr. Olin holds 8,000 shares in BerGenBio ASA. Please see the attached document for further

Bergen, Norway, 16 December 2021 – Notice is hereby given that an Extraordinary General Meeting in BerGenBio ASA (OSE:BGBIO) will be held on 6 January 2022 at 10:00 hours (CET). The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available at

In-Licensing further strengthens intellectual property estate for the treatment of Non-Small Cell Cancer (NSCLC) patients with STK11 mutations Bergen, Norway, 16 December 2021- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced today the licensing of certain intellectual property from the UT Southwestern Medical Center. The

Bergen, Norway, 14 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it will be presenting at the 12th DNB Nordic Healthcare Conference on 16th December 2021. The presentation will take place from 11:35 CET

Bergen, Norway, 13 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it is presenting updated data from the Company’s Phase II study of bemcentinib (BCBC003) in a poster presentation today at the 63rd Annual

Bergen, Norway, 17 November 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 9 November 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to

Bergen, Norway, 16 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the third quarter of 2021. A presentation and live webcast by BerGenBio’s senior management will take place at 10am CET today, please see below for details. Operational

Bergen, Norway, 9 November 2021 The Board of Directors in BerGenBio ASA (the”Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 7,000 by issuance of 70,000 new

Bergen, Norway, 9 November 2021 -BerGenBioASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 agent as treatment for patients with STK11 altered advanced/metastatic NSCLC patients without

Bergen, Norway, 9 November 2021- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place online from 10th-14th November 2021. The e-poster presentation provides

Bergen, Norway, 4 November 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for significant unmet medical needs, is pleased to announce a poster presentation at the 63[rd] Annual American Society of Hematology (ASH) Meeting, taking place 11-14[th] December 2021 in Atlanta, GA. Prof Sonja Loges will provide an

Bergen, Norway, 4 November 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the third quarter 2021 on Tuesday 16 November 2021. The briefing will take place at 10:00 am CET at: Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslo where BerGenBio’s senior management team will provide an update

Bergen, Norway, 4 October 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 30 September 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to

Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36[th] Annual Meeting, taking place online from 10-14 November 2021. Abstract titles have

Bergen, Norway, 30 September 2021 The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 13,750 by issuance of

Bergen, Norway, 7 September 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce the completion of patient recruitment into BGBC003 (ClinicalTrials.gov ID: NCT02488408), a Phase Ib/II multicenter open-label study of bemcentinib as a single agent and in combination with cytarabine or decitabine in patients

Bergen, Norway, 6 September 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 31 August 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to

Bergen, Norway, 31 August 2021 The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 1,500 by issuance of

Bergen, Norway, 26 August 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 23 August 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to

Bergen, Norway, 23 August 2021 The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 27,000 by issuance of

Bergen, Norway, 22 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical need, announces the appointment of Martin Olin as new Chief Executive Officer from 8 September 2021. Following twelve years as CEO of BerGenBio, Richard Godfrey has decided to step down as CEO of the

Bergen, Norway, 17 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the second quarter and first half of 2021. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CEST today, please see

Bergen, Norway, 6 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces changes to its clinical development team structure in preparation for late-stage clinical trials of lead candidate bemcentinib and increased activity in medical and scientific regulatory affairs. Prof. Hani Gabra has

Bergen, Norway, 4 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the second quarter and half year 2021 on Tuesday 17 August 2021. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am

Bergen, Norway, 21 July 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that pre-clinical data evaluating bemcentinib, BerGenBio’s first-in-class, potent and highly selective AXL inhibitor, for the treatment of SARS-CoV-2 infection has been presented at the 40[th] Annual American Society for Virology (ASV).

Survival 96.6% vs 91.2% Significantly reduced likelihood (69%) of progression to ventilation in higher severity cohort Significantly increased likelihood (88%) of shorter time to recovery or discharge in higher severity cohort Clinical evidence of anti-viral mechanism of action Preclinical analysis highlights bemcentinib’s potential against COVID-19 variants Bergen, Norway, 12 July 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company

Bergen, Norway, 10 July 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that preclinical data from a study investigating the anti-tumor efficacy of BerGenBio’s AXL-inhibitors bemcentinib and tilvestamab in renal cell carcinoma (RCC) was presented at the European Association of Urology 2021 virtual congress. Data from the study, conducted

Bergen, Norway, 29 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that its late-breaking abstract, outlining Phase II clinical trial of bemcentinib, a first-in-class selective oral AXL inhibitor, in hospitalised COVID-19 patients has been published at the European Congress of Clinical Microbiology &

Bergen, Norway, 28 June 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that Prof. Hani Gabra MD PhD, Chief Medical Officer of BerGenBio, will deliver a virtual presentation at the 4th Annual Next Gen Immuno-Oncology Congress, which is taking place virtually from 28

Bergen, Norway, 16 June 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 11 June 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to

Bergen, Norway, 11 June 2021 The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, today resolved to increase the Company’s share capital by NOK 7,500 by issuance

Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients Bergen, Norway, 11 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present updated preliminary survival data from the ongoing Phase II study of bemcentinib (BGBC003) in combination with low dose

Bergen, Norway, 10 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that an analysis of its Phase II clinical trial of bemcentinib, a first-in-class selective oral AXL inhibitor, in hospitalised COVID-19 patients has been selected as a late-breaking abstract at the European Congress

First recognition by a regulator of AXL-positive patients as a target population Bergen, Norway, 08 June 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1

Bergen, Norway, 7 June 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to present preclinical data on its first-in-class, fully humanised, therapeutic anti-AXL function blocking monoclonal antibody, tilvestamab, in chronic kidney disease at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress. This

Bergen, Norway, 04 June 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today presents end-of-trial data from a Phase I/II study of bemcentinib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Annual Meeting. Study

Bergen, Norway, 21[st] May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference: ABGSC Life Science Summit, virtual Date: 25 May Live presentation at 10.30hrs CET The presentation

Bergen, Norway, 20 May 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present an end-of-trial update from a Phase I/II study of bemcentinib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Annual Meeting. End of

Bergen, Norway, 19 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the first quarter of 2021. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CEST today, please see below for details.

Bergen, Norway, 18[th] May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference: 7[th] Annual Immuno-Oncology Innovation Forum (SACHS), May 18, 2021 Live presentation at 13.10 PM EDT

The trial BGBC020 shows that Bemcentinib has the potential to increase the rate of ventilator free survival in more than 50% of hospitalised COVID-19 patients, addressing the greatest challenge faced by hospitals worldwide fighting the pandemic. Ventilator Free Survival observed in 90% in bemcentinib treated patients vs 72% in SOC treated patients, in a subgroup

Bergen, Norway, 12 May 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for an e-poster presentation at the European Hematology Association (EHA) 2021 Virtual Meeting, taking place from 9-17 June 2021. The poster will provide an update from

Bergen, Norway, 11 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that pre-clinical COVID-19 data has been presented at Virtual Immunology 2021, which is taking place from 10-15 May 2021. The poster presentation illustrates findings from a pre-clinical study conducted by BerGenBio’s scientific

Bergen, Norway, 7 May 2021 – BerGenBio ASA (the “Company”) (OSE:BGBIO) announced that the Board of Directors has granted share options to employees. The annual general meeting in the Company 19 March 2021 approved the share option program and authorised the board of directors of the Company to issue shares to the Company’s employees as part

Bergen, Norway, 5 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the first quarter 2021 on Wednesday 19 May 2021. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET. The live

Bergen, Norway, 30 April 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 23 April 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to the Company’s

Bergen, Norway, 28 April 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place online from 4-8 June 2021. Abstract titles have been announced online

Bergen, Norway, 26 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a poster presentation on pre-clinical COVID-19 data has been accepted for presentation at Virtual Immunology 2021, taking place from 10-15 May 2021. Virtual Immunology 2021 is the 104[th] annual conference

Bergen, Norway, 23 April 2021; The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 6,617.30 by issuance of

Bergen, Norway, 21[st] April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference: Arctic Securities Biotech Webinar, April 22, 2021 Live presentation at 14.05hrs CET The presentation will

Day 29 follow-up of last patient enrolled has now occurred in BGBC020 and ACCORD2_002 Data receipt is ongoing and evaluation of efficacy data is underway Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit Bemcentinib was well tolerated throughout both studies,

Bergen, Norway, 30 March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that recruitment to the bemcentinib arm of the Phase two COVID-19 trial platform ACCORD, has been stopped today following review by the Scientific Advisory Committee. Due to the success of the vaccine roll out and public

Bergen, Norway – 19 Mars 2021: Annual General Meeting in BerGenBio ASA (OSE:BGBIO) was virtually held on on 19 March 2021 at 15:00 hours (CET). All proposals were resolved as presented in the notice convening the annual general meeting distributed on 25 February 2021, as further set out in the minutes from the annual general

Bergen, Norway – 15 March 2021: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting (virtually) on 19 March 2021 at 15:00 hours (CET).   The chairman of the board of directors of BerGenBio ASA (“BergenBio”), Sveinung Hole, has received proxies to vote at BerGenBio’s Annual General Meeting to be held on 19 March 2021 for a total of 7,570,836 shares, representing approx. 8.62% of the total share capital

Bergen, Norway, 12 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it has completed enrolment into Cohort C1 of its Phase II study (BGBC008) of bemcentinib in combination with anti-PD-1 therapy Keytruda[®] (pembrolizumab) in refractory non-small cell lung cancer (NSCLC) patients.

Bergen, Norway, 8 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that Richard Godfrey, CEO of BerGenBio, will be presenting at the following virtual conferences: H.C. Wainwright Global Life Sciences Conference Date: 9-10 March 2021Presentation available during the

Bergen, Norway, 6[th] March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on preclinical COVID-19 data at the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from 6-10 March 2021. The presentation was led by BerGenBio’s scientific collaborator, Professor Wendy

Bergen, Norway, 6 March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on preclinical COVID-19 data at the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from 6-10 March 2021. The presentation was led by BerGenBio’s collaborator, Professor Wendy Maury,

Bergen, Norway, 5[th] March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces the first patient dosed in an international Phase Ib trial investigating its first-in-class fully humanised anti-AXL monoclonal antibody, tilvestamab (BGB149). The objective of the study is to confirm safety, tolerability and determine a recommended

Bergen, Norway, 4[th] March 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 2 March 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to

Bergen, Norway, 4[th] March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has closed recruitment into the company sponsored randomised Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and

Bergen, Norway, 2 March 2021: The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 16 March 2020, resolved to increase the Company’s share capital by NOK 56,159.90 by issuance of 561,599

Bergen, Norway – 25 February 2021: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting [virtually] on 19 March 2021 at 15:00 hours (CET).   The notice, registration form, power of attorney and proposal from Nomination Committee are attached to this release. The notice will be sent to all registered shareholders and is available on the Company’s website: https://www.bergenbio.com/investors/general-meetings/ All shareholders are encouraged to exercise their shareholder

Bergen, Norway – 25 February 2021: Reference is made to the notice on 23 February 2021 and the Board of Directors approval of BerGenBio ASA’s (OSE:BGBIO) Annual Financial statement. The Annual Report for 2020 is available on the Company’s website: https://www.bergenbio.com/investors/  – END –  For further information, please contact:   Richard Godfrey, CEO, BerGenBio ASA +47 917 86 304  Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513  Forward looking statements   This announcement may contain forward-looking statements,

Bergen, Norway – 23 February 2021: The Board of Directors in BerGenBio ASA (the “Company”) (OSE:BGBIO) today approved the 2020 annual financial statements prepared in accordance with International Financial Reporting Standards (IFRS). The financial statements are in accordance with the preliminary 2020 annual financial statements published on 10 February 2021.   The annual report 2020 will be made available on BerGenBio ASA’s website www.bergenbio.com on 25 February 2021.

Bergen, Norway, 17 February 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for an oral virtual presentation at the annual Conference on Retroviruses and Opportunistic Infections (CROI 2021), taking place from 6-10 March 2021. The presentation will be given

Bergen, Norway, 10 February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the fourth quarter and full year 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below

Bergen, Norway, 8[th ]February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides an update on the Company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India, following

Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory lung cancer  Bergen, Norway, 29 January 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will today present an update from its Phase II study of bemcentinib in combination with anti-PD-1 therapy pembrolizumab (BGBC008) in refractory non-small cell lung cancer (NSCLC) patients at an oral presentation at the 2020 World Conference on

Bergen, Norway, 27 January 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the fourth quarter 2020 on Wednesday 10 February 2021. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET.  The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will

· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory lung cancer Updated interim data will be presented on second line patients following CPI monotherapy Bergen, Norway, 13[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present

Bergen, Norway, 12[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a member of the senior management team is presenting at the following virtual conferences: Solebury Trout Management Access Event, 6-15 January 2021 Register for the event here (https://troutaccess.com/investor.php/contact/mailcheck/hash/566554ad12a903f0f24683765aa9ed77)

Bergen, Norway, 11[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides an update on the Company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India, following

Bergen, Norway, 16 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has been accepted for an oral presentation at the 2020 World Conference on Lung Cancer Singapore (WCLC), being held from 28-31 January 2021. The oral presentation will

Bergen, Norway, 9 December 2020 – Extraordinary General Meeting in BerGenBio ASA was held virtually on 9 December 2020 at 16:00 hours (CET).  All proposals were resolved as presented in the notice convening the extraordinary general meeting distributed on 18 November 2020, as further set out in the minutes from the extraordinary general meeting attached hereto and available at https://www.bergenbio.com/investors/general- meetings/ (https://www.bergenbio.com/investors/general-%20meetings/) -Ends-  For further information, please contact:   Richard Godfrey CEO, BerGenBio ASA +47 917

Bergen, Norway, 9 December 2020 – Extraordinary General Meeting in BerGenBio ASA is being held virtually today 9 December 2020 at 16:00 hours (CET). Information on how to join the meeting: Webcast link: https://web.lumiagm.com/?fromUrl=127403163 Meeting ID: 127-403-163 Please note you must be logged in online before the meeting starts to be able to vote on

Bergen, Norway – 8[th] December 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the first patient has been enrolled with bemcentinib in the UK Research and Innovation (UKRI) funded COVID-19 ACCORD clinical study. The ACCORD study is a multicentre, seamless, Phase

Clinical benefit rate of 73% reported in second line relapsed AML patients. Overall Response OOR 45%, CR/CRi rate of 36% Median treatment duration exceeding 6 months with some patients remaining on study Bergen, Norway, 6 DECEMBER 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need,

Bergen, Norway, 3[ ]December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that members of the management team will present the company at the following virtual conferences:   The Nordic-American Life Science Conference Global Markets Day section Date: 3[rd] December 2020

Bergen, Norway, 30 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has been accepted for a poster presentation at the 62[nd]  Annual American Society of Hematology (ASH) Meeting, being held virtually from 5-8 December 2020. The poster will

Bergen, Norway – 24[th] November 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the first patient in India has been enrolled in the company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of

Bergen, Norway, 18 November 2020 – Notice is hereby given that an Extraordinary General Meeting in BerGenBio ASA will be held virtually on 9 December 2020 at 16:00 hours (CET). The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available

Bergen, Norway, 17 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the third quarter of 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below for details. Operational

Bergen, Norway, 11 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will today present an updated clinical & translational analysis from its Phase II bemcentinib and pembrolizumab combination study (BGBC008) in advanced non-small cell lung cancer (NSCLC), at an oral presentation at the

Bergen, Norway, 06 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it is hosting a Virtual R&D Day today. The online event will begin at 13.00pm CET (04.00am PST/06.00am CST). Please click here (bergenbio@consilium-comms.com?subject=I%20would%20like%20to%20attend%20the%20BerGenBio%20Virtual%20Event)to register. The event will feature

Bergen, Norway, 4 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has been accepted for a poster presentation at the 62[nd]  Annual American Society of Hematology (ASH) Meeting, being held virtually from 5-8 December 2020. The poster will

Bergen, Norway, 23[rd] October 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will host a virtual R&D Day on 06 November 2020 from 13.00 CET. The event will feature independent experts highlighting the role of AXL kinase as an

Bergen, Norway – 21 October 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the first patient has been enrolled in the company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India.   The Phase

Bergen, Norway, 15 October 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 35[th] Annual Meeting, taking place online from 9-14 November 2020. Abstract

Bergen, Norway, 14 October 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that pre-clinical data on tilvestamab, the Company’s novel function blocking, humanized anti-AXL antibody, will be presented at an ePoster presentation at the virtual 32[nd] EORTC NCI AACR (ENA) Symposium. The data presented

Bergen, Norway, 7 October 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that the first patient has been dosed and continues on therapy in a trial assessing bemcentinib in relapsed malignant mesothelioma patients, sponsored by the University of Leicester. With the

Bergen, Norway, 30 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that it has received regulatory approval from the India Regulatory Authority to proceed with a company sponsored Phase II clinical trial to assess the efficacy and safety of bemcentinib for the

Bergen, Norway, 28 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, notes that following a rise in the number of COVID-19 cases in the UK, UK Research and Innovation (UKRI) has decided to reinstate funding for the COVID-19 ACCORD clinical study in which

Bergen, Norway, 24 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that it has received approval from Norway’s Regional Ethics Committee (REK) for its company sponsored Phase II trial (BGBC020)  to assess the efficacy and safety of bemcentinib for the treatment of

Bergen, Norway, 18 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that CEO Richard Godfrey will be presenting at the Sachs Annual Biotech in Europe Forum. Date and time: Wednesday 23 September at 1pm CET. Register for the event

Bergen, Norway, 11 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that it has received regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to proceed with a company sponsored Phase II clinical trial to assess the efficacy and safety

Bergen, Norway, 1 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a member of the senior management team will be presenting at the following virtual conferences: Solebury Trout Zoomside Chat, 1[st]  September 1pm EDT (19:00 CEST)Live 1-2-1 interview

Primary endpoint of overall response rate was met in the fully recruited single arm phase II study Bergen, Norway,18 August 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces that the primary endpoint of overall response rate has been met in the BERGAMO

· Bergenbio in late stage set-up phase to sponsor and conduct a clinical study using bemcentinib in a country of high COVID-19 incidence Bergen, Norway, 28[th] July 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, notes the UK Research and Innovation’s (UKRI) decision to

Bergen, Norway, 20 July 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that the first patient has been dosed and continues on therapy in a trial assessing bemcentinib in recurrent glioblastoma (GBM). The trial is sponsored by Prof. Ichiro Nakano, MD,

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Bergen, Norway, 8 July 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, in collaboration with the ACCORD (Accelerating COVID-19 Research & Development platform) study sponsor, University Hospital Southampton NHS Foundation Trust, announces the approval of an amendment to the ACCORD-bemcentinib sub-protocol. The amended sub-protocol

Bergen, Norway, 7 July 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that Dr. Akil Jackson, Medical Director at BerGenBio, will be participating at the Sachs Associates Digital Novel Coronavirus Investment Forum on 8-9 July 2020.   Dr. Jackson will participate in a

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

6 of 7 checkpoint inhibitor refractory cAXL-positive patients report clinical benefit 12 evaluable patients for cAXL status, 7 of whom were cAXL-positive 2.5 fold improvement in mPFS in cAXL-positive patients Cohort A data-update mOS in cAXL-positive patients of 17.3 months. Data presented today at the virtual Next Gen Immuno-Oncology Congress Bergen, Norway, 25 June 2020 –

Bergen, Norway, 24 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces a change to the presentation time of the Company’s oral virtual presentation at the upcoming Next Gen Immuno-Oncology Congress. Updated details are as follows: Date and time: 25 June 2020, 12.00

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Bergen, Norway, 15 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for oral virtual presentation at the 3[rd] Annual Next Gen Immuno-Oncology Congress, which takes place from 25-26 June 2020. The presentation to

Bergen, Norway, 9 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that CEO Richard Godfrey will present at ABG Sundal Collier Virtual Oncology Seminar on 10 June 2020 at 11:45 CET. The presentation will be made available to view at www.bergenbio.com in

Bergen, Norway – 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as

Bergen, Norway, 29 May 2020 – Notice is hereby given of an Extraordinary General Meeting in BerGenBioASA will be held on 19 June 2020 at 15:00 hours (CET) at the Company’s offices in Møllendalsbakken 9, 5009 Bergen. The notice, registration form and power of attorney are attached to this release. The notice will be sent

Bergen, Norway, 19 May 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces its results for the first quarter 2020. A live webcast presentation by the Company’s management will take place today at 10:00 am CET, please see below for details. Richard Godfrey, Chief Executive

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Bergen, 4 May 2020: Reference is made to the stock exchange notice today 4 May 2020 by BerGenBio ASA (“BerGenBio” or the “Company”), regarding a contemplated private placement. An updated Corporate Presentation is available at our website under the investor section. https://www.bergenbio.com/investors/presentations/ For further information, please contact: Richard Godfrey, CEO richard.godfrey@bergenbio.com +47 917 86 304  

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Bemcentinib selected as first candidate to be tested through new ACCORD study The Phase II clinical trial initiative to rapidly investigate bemcentinib’s efficacy and safety in hospitalised COVID-19 patients Study to be funded by the UK Department of Health and Social Care and UK Research and Innovation Study to be managed by CRO, IQVIA BerGenBio

Bemcentinib selected as first candidate to be tested through new ACCORD study The Phase II clinical trial initiative to rapidly investigate bemcentinib’s efficacy and safety in hospitalised COVID-19 patients Study to be funded by the UK Department of Health and Social Care and UK Research and Innovation Study to be managed by CRO, IQVIA BerGenBio

Bergen, Norway, 14 April 2020 – The board of directors in BerGenBio ASA (the “Company”) (OSE:BGBIO) has granted options to employees. The annual general meeting in the Company at 16 March 2020 approved the share options program and authorised the board of directors of the Company to issue share options to the Company’s employees as

Bergen, Norway, 30 March 2020 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 13 March 2020 where the Company announced the final results of the subsequent offering. A total of 6,397 shares were issued in the subsequent offering at a subscription price of NOK 18.00

Bergen, Norway, 27 March 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, provides an update on its business and operations considering the ongoing COVID-19 outbreak. Summary BerGenBio’s priority remains the safety and health of its employees and their families, and to continue the Company’s

Bergen, Norway, 16 March 2020 – Annual general meeting of BerGenBio ASA was held at Clarion Hotel Bergen Airport, Flyplassveien 551, 5869 Bergen, on 16 March 2020.   All proposals were resolved as presented in the notice convening the annual general meeting distributed on 24 February 2020, as further set out in the minutes from

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Bergen, Norway, 2 March 2020 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 20 February 2020 where the Company announced that an extraordinary general meeting had resolved to increase the Company’s share capital in connection with Tranche 2 of the private placement announced by the Company

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Bergen, Norway, 11 February 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2019. A presentation and live webcast by the Company’s management will take place today at 10.00 am CET in Oslo, please see below

Bergen, Norway, 5 February 2020 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 30 January 2020 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the private placement. A total of

Bergen, Norway, 30 January 2020 – A Extraordinary General Meeting in BerGenBio ASA will be held on 20 February 2020 at 17:00 hours (CET) at the company’s offices in Møllendalsbakken 9, 5009 Bergen. The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

· First stage clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL inhibitor bemcentinib in combination with Keytruda[®] in patients with advanced NSCLC who have failed checkpoint inhibitor therapy. Criteria were met for expansion of this cohort to a second stage. Bergen, Norway, 15 January 2019 – BerGenBio ASA (OSE: BGBIO) a

· Phase II trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC)  in elderly AML patients unfit for intensive therapy is well tolerated and shows promising efficacy Long duration of response (>9.9 mo, still maturing) with 50% CR/CRi in 6 evaluable newly diagnosed patients receiving the bemcentinib-LDAC combination. Clinical benefit demonstrated in >2L relapsed and

· BerGenBio’s proprietary Composite AXL Tumor-Immune Score predicts patients that have significantly prolonged clinical benefit Primary endpoint of ORR in cohort A met, in predominantly PD-L1 low/negative patients Combination is 5-fold more active in composite AXL positive patients (33% ORR) vs AXL negative patients (7% ORR) Secondary endpoint, median Progression Free Survival of 8.4 months in

 Primary endpoint, Overall Response Rate, has been met in predominantly PD-L1 negative/low patients  Secondary endpoint, median Progression Free Survival, exceeds expectations in AXL positive patients  Data to be presented at Society for Immunotherapy of Cancer 34th Annual Meeting on 8 November 2019 Bergen, Norway, 6 November 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company

Bergen, Norway 22nd October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today announces that the U.S. Food and Drug Administration (FDA) has approved Fast Track Designation for bemcentinib for the treatment of elderly patients with acute myeloid leukaemia (AML) whose disease has relapsed. There

Bergen, Norway, 27 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is to provide study updates in two poster presentations from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, at the European Society for Medical

Bergen, Norway, September 10 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces today that Richard Godfrey, BergenBio’s chief executive officer, will present at the H.C. Wainwright 21st Annual Global Life Sciences Conference today, September 10, 2019.  Date: Tuesday, September 10, 2019Time: 5.15pm CESTLocation: Lotte New

Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will present study updates from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer (NSCLC) at the 2019 World Conference

Bergen, Norway, 3 September 2019 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 28 August 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise options pursuant to the

Bergen, Norway, 2 September 2019. BerGenBio ASA (the”Company”) (OSE: BGBIO). Reference is made to the stock exchange notice dated 28 August 2019 and primary insiders exercise of share options which expire in 2019. Primary Insider Richard Godfrey (CEO) exercised 225,000 options equal to 225,000 shares. To cover costs related to the exercise, Richard Godfrey transferred

Bergen, Norway, 28 August 2019. The Board of Directors of BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorisation granted by the general meeting on 13 March 2019, resolved to increase the Company’s share capital by NOK 54,000 by issuance of

Bergen, Norway, 1 July 2019 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 28 June 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise options pursuant to the

Bergen, Norway, 28 June 2019: BerGenBio ASA (the “Company”) (OSE: BGBIO) today announces that in order to to fulfil the Company’s obligations under its option scheme, the Board of Directors has resolved to increase the Company’s share capital by NOK 9,000 by issuance of 90,000 new shares. The new shares have been issued to an

Bergen, Norway, 21 June 2019 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 13 June 2018 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the private placement. A total of

Bergen, Norway, 20 June 2019. Primary Insider Sveinung Hole has today purchased 2,950 shares in BerGenBio ASA at an average price of NOK 13.44. Following this transaction, Sveinung Hole holds in total 107,394 shares in BerGenBio ASA, including 104,444 shares owned by Svev AS, corresponding to 0.18% of the shares in BerGenBio ASA. -End- Contacts

Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy shows significant efficacy Preliminary responses reported in 6/14 (43%) patients, with CR/CRi in 4/14 (29%) patients;

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly AML patients unfit for intensive therapy shows promising efficacy 6 out of 13 (46%) patients receiving LDAC combination achieved an Overall Response Rate (ORR) of 46% 3 out of 12 evaluable patients receiving decitabine combination achieved an ORR of 25% ORR significantly higher

Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy Promising clinical activity continues to be seen, particularly in patients with AXL positive tumours including those with low or no PD-L1 expression Chicago, USA, 02 June 2019 –

Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in combination with pembrolizumab, data to be presented includes safety, response rates and overall survival Acute Myeloid Leukaemia (AML) trial of bemcentinib in combination with low dose AraC chemotherapy or decitabine

Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy (Cohort A, NCT03184571) First stage previously met efficacy endpoint Second stage enrolled a further 24 patients for a total of 48; efficacy and biomarker data updates expected at medical conferences during 2019 Bergen, Norway, 08 May 2019 – BerGenBio ASA (OSE:

Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA Accepted for presentation at ASCO in June 2019 Bergen, Norway, 23 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that the Company and its collaborators will present

Bergen, Norway, 15 April 2019 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 12 April 2019 where the Company announced that the Board of Directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to

Bergen, Norway, April 09 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers, announces that Richard Godfrey, BerGenBio’s Chief Executive Officer, will present an overview of the Company at the H.C. Wainwright Global Life

  First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy New cohort added under existing collaborative agreement with Merck assessing the combination in previously treated advanced NSCLC Decision to extend driven by encouraging

Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL’s role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR Selective AXL inhibitor, bemcentinib, shown to reverse AXL’s effects, thus acting synergistically with immune cells and anti-cancer therapies Data further strengthens broad development opportunities for bemcentinib both as

Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for intensive therapy Bemcentinib + low-dose cytarabine (LDAC) achieves efficacy endpoint, warrants further investigation Three out of 10 evaluable patients (30%) reported Complete Responses (CR/CRi) Responses occurred early, improved over time and included poor risk, previously treated patients No overlapping or

Bergen, Norway, 14 March 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces today changes made to its executive team and Board of Directors, to strengthen the organisation and prepare it for late stage clinical trials towards the second half of 2019.

ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for antibody drug conjugate (ADC) development Phase I dose escalation and expansion trial will evaluate ADCT-601 in 75 cancer patients ADCT-601 is BerGenBio’s third clinical candidate targeting AXL Bergen, Norway, January 21 2019 – BerGenBio ASA (OSE:BGBIO), announces that the first patient has been dosed

BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio’s second novel clinical candidate targeting AXL Phase I study will investigate safety and pharmacokinetics in healthy volunteers Bergen, Norway, January 9 2019 – BerGenBio ASA (OSE:BGBIO),a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat

Bergen, Norway, Jan 8th 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces that the Company will be presenting a corporate overview at the Biotech Showcase 2019 in San Francisco today at 10:00 am PST. The presentation will webcast live and the

Phase II monotherapy study of bemcentinib in high-risk MDS & AML Will enrol up to 43 patients at leading MDS centres across Europe Investigator sponsored trial led by Prof. Uwe Platzbecker Bergen, Norway, Jan 4th 2019 – BerGenBio ASA (OSE: BGBIO), announces that the first patient has been dosed in an investigator-initiated phase II trial of

Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia AXL biomarker correlation supports bemcentinib’s proposed MoA, potential for Companion Diagnostic Significant milestones expected over next 12 months Bergen, Norway, 12 Dec 2018 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class

43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) Phase II trial continues in combination with chemotherapeutics in first line AML Bemcentinib with decitabine cohort has completed recruitment, data will be submitted for presentation at upcoming medical congress Bergen, Norway, 3 Dec 2018 – BerGenBio ASA (OSE:

Further senior organisational changes made in preparation for advancing bemcentinib into the next stage of clinical development in multiple aggressive cancers  Bergen, Norway, 22nd November 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as

Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective AXL inhibitor bemcentinib + KEYTRUDA in previously treated advanced NSCLC patients Median progression-free-survival (mPFS) of 5.9 months in AXL positive vs 3.3 months in AXL negative patients (~80% improvement) Predominantly PD-L1 negative or weak-positive patient population  Bergen, Norway, 6 November

Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC Analysis comprises stage 1 (n=24) in PhII trial in 2L advanced NSCLC Stage 2 open and enrolling Bergen, Norway, 2 November 2018 – BerGenBio ASA (OSE:BGBIO) announces that the analysis of the first stage of its Phase II clinical

Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second line NSCLC. Melanoma combination study reports safety and efficacy. Bergen, Norway, 22 October 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators have presented interim clinical and biomarker data from BerGenBio’s Phase II clinical programme with bemcentinib (BGB324), a

Bergen, Norway, 9 October 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical and biomarker data from its Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor at the ESMO 2018 Congress in Munich (19 – 23 October 2018).  Pre-clinical data on the role of

Bergen, Norway, 5 October 2018- BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in the second stage of the phase II trial (BGBC008) evaluating the Company’s selective AXL inhibitor bemcentinib in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with previously treated advanced adenocarcinoma of the lung (non-small cell lung cancer, NSCLC)

Overall response rate of 40% with the bemcentinib/KEYTRUDA combination observed in AXL-positive, previously treated NSCLC patients, including PD-L1 negative patients who are not expected to benefit from KEYTRUDA monotherapyMedian PFS of patients receiving the bemcentinib/TARCEVA combination in first line has surpassed that of TARCEVA monotherapyEncouraging efficacy reported for bemcentinib in combination with docetaxel chemotherapy in

Bergen, Norway, 5 September 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer (NSCLC) at the 19th World Conference on Lung Cancer (WCLC) in Toronto (23

Bergen, Norway, August 30th, 2018 – BerGenBio ASA (OSE:BGBIO), announces that Richard Godfrey, CEO of BerGenBio, is scheduled to present an overview of the Company’s business and ongoing phase II clinical development programme with its first-in-class selective AXL inhibitor bemcentinib at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright &

Bergen, Norway, 14 August 2018 – BerGenBio ASA (OSE:BGBIO) will announce its results for the second quarter and first half 2018 on Tuesday, 21 August 2018. A presentation by BerGenBio’s senior management team will take place at 10 am CEST at: Felix Konferansesenter, Bryggetorget 3, 0125 Oslo The presentation will webcast live and the link